CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Regional Analysis

To learn more about this report, Request sample copy

North America currently dominates the global critical limb ischemia treatment market. The region is expected to account for 40.1% in 2024 and is expected to continue its stronghold over the forecast period. The region has a well-established healthcare infrastructure and high healthcare expenditure which enables early adoption of latest medical technologies. There is a strong presence of key market players in the region who continue to invest heavily in R&D for developing advanced treatment options. Additionally, growing geriatric population and associated rise in the prevalence of diabetes and peripheral artery disease have been primary factors driving the growth of treatments in North America.

Among emerging regions, Asia Pacific is poised to exhibit the fastest growth through the next five to seven years. Rapid economic development and improving access to healthcare across major Asian countries have increased demand for critical limb ischemia treatment. India and China together account for over one-third of global diabetes cases, fueling growth opportunities. Initiatives by regional governments to strengthen healthcare systems along with increasing healthcare spending are positively impacting the market growth. Further, growing medical tourism across Asia Pacific due to the availability of low-cost treatment is attracting patients from developed markets of North America and Western Europe. This has encouraged local players to invest in building capabilities to cater to international standards. While pricing pressures exist, the large patient pool and rising affordability are aiding Asia Pacific to emerge as the fastest growing regional market.